Key message: interferon alpha improves both disease-free survival and overall survival of people with high-risk cutaneous melanoma. Interferon is also valid as a reference standard for future trials of other new treatments.
Cutaneous melanoma is a type of skin cancer that’s on the rise in all Western countries and carries with it a poor chance of survival for those in whom the cancer has spread, with around 10% surviving longer than five years. For those whose cancer has not spread, their outlook after surgery is variable; between 40% and 90% are alive after five years. Interferon alpha is the only drug approved for adjuvant (additional) treatment of high-risk cutaneous melanoma after surgery, but not enough has been known about its benefits for it to be offered as a standard treatment. Continue reading